Biopharmaceuticals Analyst Chen and Biotechnology Watsek, along with Dr. Giancarlo Moscol, Department of Breast Medical Oncology at the University of Texas, discuss the competitive landscape of breast cancer treatment (relevant companies, ARVN and PFE) on an Analyst/Industry conference call to be held on April 15 at 1 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas Partners with Novartis on Prostate Cancer Therapy
- Arvinas enters exclusive strategic license agreement with Novartis for ARV-766
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
- Arvinas Appoints New Chief Medical Officer for Clinical Programs
- Arvinas names Noah Berkowitz as Chief Medical Officer
